论文部分内容阅读
目的 :比较替硝唑三联疗法与甲硝唑三联疗法对根除幽门螺杆菌的疗效及不良反应。方法 :将内镜及病理证实的慢性胃炎患者 85例随机分成A ,B组 ,A组即替硝唑三联组 (替硝唑 0 .5 g ,bid ,阿莫西林 1.0 g ,bid ,次枸橼酸铋钾 2 2 0mg ,bid ,疗程 2周 ) ,B组即甲硝唑三联组 (甲硝唑 0 .4g ,bid ,阿莫西林 1.0 g ,bid ,次枸橼酸铋钾2 2 0mg ,bid ,疗程 2周 )。 结果 :A组幽门螺杆菌根除率 83.7% (36 /4 3) ,B组为 76 .2 % (32 /4 2 ) ;对疼痛的缓解率分别为 86 .2 % (2 5 /2 9)和 84.0 % (2 1/2 5 ) ,两组比较均无明显差异 (P >0 .0 5 )。不良反应发生率B组为 31.0 %(13/4 2 ) ,明显高于A组的 11.6 % (5 /4 3) ,两组比较有明显差异 (P <0 .0 5 )。结论 :本研究结果显示A组幽门螺杆菌根除率及疼痛的缓解率略高于B组 ,而不良反应则明显低于B组 ,两组比较有显著性差异 (P <0 .0 5 )。
Objective: To compare the efficacy and adverse reactions of tinidazole triple therapy and metronidazole triple therapy in the eradication of Helicobacter pylori. Methods: Eighty-five patients with chronic gastritis confirmed by endoscopy and pathology were randomly divided into group A and group B. Group A was treated with tinidazole triplet (tinidazole 0.5 g, bid, amoxicillin 1.0 g, bid, Bismuth potassium citrate 220mg, bid, course of treatment for 2 weeks), group B metronidazole triple group (metronidazole 0.4g, bid, amoxicillin 1.0 g, bid, bismuth potassium citrate 220 mg , bid, treatment for 2 weeks). Results: The H. pylori eradication rate was 83.7% (36/43) in group A and 76.2% (32/42) in group B. The pain relief rates were 86.2% (25/29) And 84.0% (2 1/2 5) respectively. There was no significant difference between the two groups (P> 0.05). The incidence of adverse reactions in group B was 31.0% (13/42), which was significantly higher than that in group A (11.6%, 5/4 3). There was significant difference between the two groups (P <0.05). Conclusion: The results of this study showed that the response rate of Helicobacter pylori eradication and pain in group A was slightly higher than that in group B, while the adverse reaction was significantly lower than that in group B, with significant difference between the two groups (P <0.05).